1, 2, 3-triazole-derived androgen receptor antagonists (12a-f)

These compounds present an excellent starting point for the development of prostate cancer therapeutics for both androgen dependent and independent forms of this disease.

Contributors

Institute
Deakin University
Cat. #: 157777
Tool sub type: Antitumoral
Research Fields: Cancer;Neurobiology;Other
Product description: Prostate Cancer is the most commonly diagnosed cancer in men worldwide and is the fourth most common cancer diagnosed overall. Current treatments include castration, chemotherapy, radiation therapy and androgen blockade. Developing Androgen receptor antagonists falls under andogen blockade therapy. A common feature of AR Antagonists is the electron deficient 3,4-substituted aryl ring, and often consists of a trifluoromethyl group at the 3-position while a nitrile or nitro group is present at the 4-position. It can be a challenge to access aryl withdrawn N-phenyl amides via peptide coupling, providing moderate yields due to the nonnucleophilic anilinic nitrogen. Therefore, the inventors believe that replacement of the amide moiety of bicalutamide with a 1,2,3-triazole (accessed via very high yielding click chemistry') may have synthetic and biological value. Replacing amides with 1,2,3-triazole is believed to show a number of benefits: – Increasing synthetic yield – Proving suitability of the 1,2,3-triazole as an isosteric replacement of the N-phenyl amide – Minimising the peptidic nature of these compounds which can result in resistance to in vivo metabolism The group present a number of novel androgen receptor antagonists which incorporate a 1,2,3-triazole replacement for the Nphenyl amide. The in silico docking of these compounds into the human androgen receptor (hAR) has been carried out, and their determined IC50 values for androgen responsive (LNCaP) and androgen independent (PC-3) cell lines has also been reported. The molecules 12af, possess promising anti-proliferative properties against LNCaP cells (IC50 3445 lM) and PC-3 cells (IC50 29151 lM).Information can be found in their publication PMID: 25301770. These compounds present an excellent starting point for the development of prostate cancer therapeutics for both androgen dependent and independent forms of this disease. Publication – PMID: 25301770.
Molecular weight: 12a: 477.0643 12b: 475.0713 12c: 434.1162 12d: 406.0835 12e: 437.089 12f: 457.0728
Primary target: Androgen Receptors
Shipping conditions: Dry Ice
References:

Altimari et al. 2014. Bioorg Med Chem Lett. 24(21):4948-53. PMID: 25301770.

Related Tools for Small molecules

Cat. # Tool Name
151831 Protein Kinase D inhibitor CRT0066101 Small Molecule (Tool Compound) Key Info View Tool
151834 Antitumoral Quinol1h Small Molecule (Tool Compound) Key Info View Tool
152544 Protein Kinase D inhibitor CRT5 (CRT0066051) Small Molecule (Tool Compound) Key Info View Tool
152709 Dual DNA-PK/PI3K inhibitor KU-0060648 Small Molecule (Tool Compound) Key Info View Tool
152754 CDK2 inhibitor NU6301 Small Molecule (Tool Compound) Key Info View Tool

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.